J.P. Morgan projects that the GLP-1 drug market in China, India, and Brazil could reach $22 billion by 2035, driven by ...
Dr Reddy's Laboratories has introduced two new generic versions of Ozempic, named Obeda Pro and Obeda Plus, to address supply ...
AbbVie announced promising results for its experimental drug lutikizumab in reducing skin lesions from hidradenitis ...
Telitacicept met the study's main goal and largely preserved kidney function over two years, while patients on placebo saw a ...
The deal follows positive mid-stage results for Gilead's experimental pill for chronic bowel disease, emvistegrast, on Monday ...
Novartis presents disappointing data for remibrutinib, its oral multiple sclerosis drug, showing lower than anticipated ...
Dr Reddy’s Laboratories is set to resume supplies of its semaglutide generic, Obeda, following production disruptions, ...
New Delhi: Zydus Lifesciences' US-arm is undertaking a voluntary recall of anti-inflammatory drug. Hydrocortisone Sodium Succinate after the product failed to meet impurity and degradation ...
Bengaluru: AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment for adults with immunoglobulin A nephropathy, a rare kidney disease that can ...
Mumbai: Sun Pharmaceutical Industries plans to raise 100 billion rupees ($1.05 billion), including a greenshoe option of 30 billion rupees, through two tranches of five-year and one-day bonds, three ...
Explore how cheap Chinese antibiotics threaten the survival of Europe's final major penicillin manufacturing facility in ...
The product is a generic version of Bristol-Myers Squibb’s Paraplatin and will be manufactured by Chennai-based contract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results